We are live on ! Find out more
GIP

Greatmark Investment Partners Portfolio holdings

AUM $906M
1-Year Est. Return 16.08%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+16.08%
3 Year Est. Return
+61.99%
5 Year Est. Return
+81.88%
10 Year Est. Return
+373.56%
AUM
$250M
AUM Growth
+$6.77M
Cap. Flow
+$3.13M
Cap. Flow %
1.25%
Top 10 Hldgs %
40.75%
Holding
110
New
8
Increased
33
Reduced
35
Closed
3

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$711K
2
HP icon
Helmerich & Payne
HP
+$519K
3
GILD icon
Gilead Sciences
GILD
+$516K
4
GWW icon
W.W. Grainger
GWW
+$510K
5
QCOM icon
Qualcomm
QCOM
+$348K

Top Sells

Rank Stock Value
1
NOV icon
NOV
NOV
+$710K
2
AFL icon
Aflac
AFL
+$218K
3
AAPL icon
Apple
AAPL
+$214K
4
TGNA
TEGNA Inc
TGNA
+$213K
5
JNJ icon
Johnson & Johnson
JNJ
+$172K

Sector Composition

Rank Sector Weight
1 Financials 21.89%
2 Technology 21.19%
3 Healthcare 14.59%
4 Industrials 11.23%
5 Consumer Staples 8.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CL icon
76
Colgate-Palmolive
CL
$73.2B
$374K 0.15%
5,042
– –
FLTB icon
77
Fidelity Limited Term Bond ETF
FLTB
$414M
$364K 0.15%
7,225
– –
SHW icon
78
Sherwin-Williams
SHW
$84.7B
$358K 0.14%
3,060
– –
COHR
79
DELISTED
Coherent Inc
COHR
$337K 0.14%
1,500
– –
BIIB icon
80
Biogen
BIIB
$29.8B
$327K 0.13%
1,205
+200
+20% +$52.9K
LLY icon
81
Eli Lilly
LLY
$995B
$305K 0.12%
3,707
-225
-6% -$18.4K
BSV icon
82
Vanguard Short-Term Bond ETF
BSV
$44.5B
$303K 0.12%
3,800
+275
+8% +$22K
SCHW
83
Charles Schwab
SCHW
$183B
$301K 0.12%
7,000
– –
VTI icon
84
Vanguard Morningstar Total Stock Market ETF
VTI
$669B
$296K 0.12%
2,380
– –
DUK icon
85
Duke Energy
DUK
$97.2B
$295K 0.12%
3,524
– –
ABT icon
86
Abbott
ABT
$184B
$293K 0.12%
6,032
– –
TRV icon
87
Travelers Companies
TRV
$78.2B
$278K 0.11%
2,200
– –
NEM icon
88
Newmont
NEM
$99.7B
$269K 0.11%
8,290
– –
HNNA icon
89
Hennessy Advisors
HNNA
$77.7M
$239K 0.1%
+15,749
New +$253K
AN icon
90
AutoNation
AN
$7.21B
$231K 0.09%
+5,490
New +$223K
PFE icon
91
Pfizer
PFE
$142B
$231K 0.09%
7,255
– –
COST icon
92
Costco
COST
$422B
$229K 0.09%
1,435
– –
KMB icon
93
Kimberly-Clark
KMB
$36.6B
$229K 0.09%
1,774
+1
+0.1% +$130
IBM icon
94
IBM
IBM
$214B
$228K 0.09%
1,549
– –
ORCL icon
95
Oracle
ORCL
$399B
$228K 0.09%
4,540
– –
AMGN icon
96
Amgen
AMGN
$204B
$227K 0.09%
1,320
– –
WFM
97
DELISTED
Whole Foods Market Inc
WFM
$227K 0.09%
+5,395
New +$196K
VZ icon
98
Verizon
VZ
$198B
$220K 0.09%
4,929
+400
+9% +$18.6K
NIQ
99
DELISTED
NUVEEN INTERMEDIATE DURATION QUALITY MUNICIPAL TERM FUND
NIQ
$211K 0.08%
16,250
– –
NVG icon
100
Nuveen AMT-Free Municipal Credit Income Fund
NVG
$2.67B
$159K 0.06%
10,479
– –
1 2 3
4
5

Similar funds

SWM
Stockman Wealth Management Billings, Montana $906M AUM 22.23% 1-Year Est. Return
SDWMA
Schneider Downs Wealth Management Advisors Pittsburgh, Pennsylvania $907M AUM 19.33% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
HIGP
Hill Investment Group Partners St. Louis, Missouri $906M AUM 20.13% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
BDP
Brehaut David Pascal $908M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM

Greatmark Investment Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Greatmark Investment Partners held 110 positions worth $250M, up 2.8% from $243M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Greatmark Investment Partners's Q2 2017 filing shows 8 new, 33 increased, 35 reduced and 3 closed positions. Its largest new stake was W.W. Grainger: 2,700 shares worth $487K. The largest sale was NOV, an estimated $710K.

By sector, the portfolio is most concentrated in Financials at 22% of assets, up from 21% a quarter earlier, followed by Technology and Healthcare.

  • Greatmark Investment Partners's largest Q2 2017 buy was W.W. Grainger: 2,700 shares worth $487K.
  • Greatmark Investment Partners added most to Teva Pharmaceuticals in Q2 2017, an estimated $711K increase.
  • Greatmark Investment Partners's biggest Q2 2017 reduction was Aflac, cutting an estimated $218K.
  • Greatmark Investment Partners fully exited NOV in Q2 2017, selling an estimated $710K.
  • Greatmark Investment Partners's ten largest holdings make up 41% of its $250M portfolio in Q2 2017.
  • Greatmark Investment Partners opened 8 new positions and closed 3 in Q2 2017.
  • Greatmark Investment Partners's portfolio value rose 2.8% quarter-over-quarter to $250M.

Based on Greatmark Investment Partners's 13F filing for Q2 2017, filed 1 Aug 2017.